Energy and the environment are intimately related and hotly debated issues. Today’s crude oil-based economy for the manufacture of fuels, chemicals and materials will not have a sustainable future. The over-use of oil products has done a great damage to the environment. Faced with the twin challenges of sustaining socioeconomic development and shrinking the environmental footprint of chemicals and fuel manufacturing, a major emphasis is on either converting biomass into low-value, high-volume biofuels or refining it into a wide spectrum of products. Using carbon for fuel is a flawed approach and unlikely to achieve any nation’s socioeconomic or environmental targets. Biomass is chemically and geographically incompatible with the existing refining and pipeline infrastructure, and biorefining and biofuels production in their current forms will not achieve economies of scale in most nations. Synergistic use of crude oil, biomass, and shale gas to produce fuels, value-added chemicals, and commodity chemicals, respectively, can continue for some time. However, carbon should not be used as a source of fuel or energy but be valorized to other products. In controlling CO₂emissions, hydrogen will play a critical role. Hydrogen is best suited for converting waste biomass and carbon dioxide emanated from different sources, whether it be fossil fuel-derived carbon or biomass-derived carbon, into fuels and chemicals as well as it will also lead, on its own as energy source, to the carbon negative scenario in conjunction with other renewable non-carbon sources. This new paradigm for production of fuels and chemicals not only offers the greatest monetization potential for biomass and shale gas, but it could also scale down output and improve the atom and energy economies of oil refineries. We have also highlighted the technology gaps with the intention to drive R&D in these directions. We believe this article will generate a considerable debate in energy sector and lead to better energy and material policy across the world.Graphic

Most medications targeting optic neuropathies are administered as eye drops. However, their corneal penetration efficiencies are typically < 5%. There is a clear, unmet need for novel transcorneal drug delivery vehicles. To this end, we have developed a stimulus-responsive, in situ-forming, nanoparticle-laden hydrogel for controlled release of poorly bioavailable drugs into the aqueous humor of the eye. The hydrogel is formulated as a composite of hyaluronic acid (HA) and methylcellulose (MC). The amphiphilic nanoparticles are composed of poly(ethylene oxide) (PEO) and poly(lactic acid) (PLA). Experimental design aided the identification of hydrogel composition and nanoparticle content in the formulation, and the formulation reliably switched between thixotropy and temperature-dependent rheopexy when it was tested in a rheometer under conditions that simulate the ocular surface, including blinking. These properties should ensure that the formulation coats the cornea through blinking of the eyelid and facilitate application of the medication as an eye drop immediately prior to the patient’s bedtime. We subsequently tested the efficacy of our formulation in whole-eye experiments by loading the nanoparticles with cannabigerolic acid (CBGA). Our formulation exhibits over a 300% increase in transcorneal penetration over control formulations. This work paves the way for the introduction of novel products targeting ocular diseases to the market.

Three kraft lignins were subjected to oxidative depolymerization using a magnetically separable and reusable nitroxyl radical catalyst under greener conditions without the use of additional alkali.

Modular polyketide synthases (mPKSs) build functionalized polymeric chains, some of which have become blockbuster therapeutics. Organized into repeating clusters (modules) of independently-folding domains, these assembly-line-like megasynthases can be engineered by introducing non-native components. However, poor introduction points and incompatible domain combinations can cause both unintended products and dramatically reduced activity. This limits the engineering and combinatorial potential of mPKSs, precluding access to further potential therapeutics. Different regions on a given mPKS domain determine how it interacts both with its substrate and with other domains. Within the assembly line, these interactions are crucial to the proper ordering of reactions and efficient polyketide construction. Achieving control over these domain functions, through precision engineering at key regions, would greatly expand our catalogue of accessible polyketide products. Canonical mPKS domains, given that they are among the most well-characterized, are excellent candidates for such fine-tuning. The current minireview summarizes recent advances in the mechanistic understanding and subsequent precision engineering of canonical mPKS domains, focusing largely on developments in the past year.